CN116139331A - Multifunctional wound repair dressing loaded with bioactive glass and preparation method thereof - Google Patents
Multifunctional wound repair dressing loaded with bioactive glass and preparation method thereof Download PDFInfo
- Publication number
- CN116139331A CN116139331A CN202310031729.4A CN202310031729A CN116139331A CN 116139331 A CN116139331 A CN 116139331A CN 202310031729 A CN202310031729 A CN 202310031729A CN 116139331 A CN116139331 A CN 116139331A
- Authority
- CN
- China
- Prior art keywords
- solution
- polymer material
- bioactive glass
- modified polymer
- quaternary ammonium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000005313 bioactive glass Substances 0.000 title claims abstract description 36
- 230000037314 wound repair Effects 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000002861 polymer material Substances 0.000 claims abstract description 30
- 239000004005 microsphere Substances 0.000 claims abstract description 23
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 16
- 230000035876 healing Effects 0.000 claims abstract description 13
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims abstract description 5
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 39
- 238000003756 stirring Methods 0.000 claims description 30
- 239000000017 hydrogel Substances 0.000 claims description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 239000008367 deionised water Substances 0.000 claims description 24
- 229910021641 deionized water Inorganic materials 0.000 claims description 24
- 229920001661 Chitosan Polymers 0.000 claims description 23
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 claims description 20
- 206010052428 Wound Diseases 0.000 claims description 16
- 208000027418 Wounds and injury Diseases 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- PUVAFTRIIUSGLK-UHFFFAOYSA-M trimethyl(oxiran-2-ylmethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC1CO1 PUVAFTRIIUSGLK-UHFFFAOYSA-M 0.000 claims description 15
- 239000012043 crude product Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 239000004530 micro-emulsion Substances 0.000 claims description 14
- ZHJGWYRLJUCMRT-UHFFFAOYSA-N 5-[6-[(4-methylpiperazin-1-yl)methyl]benzimidazol-1-yl]-3-[1-[2-(trifluoromethyl)phenyl]ethoxy]thiophene-2-carboxamide Chemical compound C=1C=CC=C(C(F)(F)F)C=1C(C)OC(=C(S1)C(N)=O)C=C1N(C1=C2)C=NC1=CC=C2CN1CCN(C)CC1 ZHJGWYRLJUCMRT-UHFFFAOYSA-N 0.000 claims description 13
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 13
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- DQWPFSLDHJDLRL-UHFFFAOYSA-N triethyl phosphate Chemical compound CCOP(=O)(OCC)OCC DQWPFSLDHJDLRL-UHFFFAOYSA-N 0.000 claims description 11
- 102000008186 Collagen Human genes 0.000 claims description 10
- 108010035532 Collagen Proteins 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 229920001436 collagen Polymers 0.000 claims description 10
- 229920000159 gelatin Polymers 0.000 claims description 10
- 239000008273 gelatin Substances 0.000 claims description 10
- 235000019322 gelatine Nutrition 0.000 claims description 10
- 235000011852 gelatine desserts Nutrition 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000004108 freeze drying Methods 0.000 claims description 8
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 239000000463 material Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 5
- 239000007795 chemical reaction product Substances 0.000 claims description 5
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 5
- 239000000178 monomer Substances 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 4
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 4
- 230000029663 wound healing Effects 0.000 claims description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 3
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 3
- JRBPAEWTRLWTQC-UHFFFAOYSA-N dodecylamine Chemical compound CCCCCCCCCCCCN JRBPAEWTRLWTQC-UHFFFAOYSA-N 0.000 claims description 3
- 229920002674 hyaluronan Polymers 0.000 claims description 3
- 229960003160 hyaluronic acid Drugs 0.000 claims description 3
- 235000010413 sodium alginate Nutrition 0.000 claims description 3
- 239000000661 sodium alginate Substances 0.000 claims description 3
- 229940005550 sodium alginate Drugs 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- 229940045110 chitosan Drugs 0.000 claims description 2
- 229960002086 dextran Drugs 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 239000012467 final product Substances 0.000 claims description 2
- 229940014259 gelatin Drugs 0.000 claims description 2
- 238000005245 sintering Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- XIPRTRJDLZVSHO-UHFFFAOYSA-N aminooxy(phenoxy)borinic acid Chemical compound NOB(O)OC1=CC=CC=C1 XIPRTRJDLZVSHO-UHFFFAOYSA-N 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 1
- 239000012304 carboxyl activating agent Substances 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 230000004071 biological effect Effects 0.000 abstract description 5
- 230000002194 synthesizing effect Effects 0.000 abstract 2
- 238000003980 solgel method Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 35
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- 239000007987 MES buffer Substances 0.000 description 10
- 125000001453 quaternary ammonium group Chemical class 0.000 description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000012190 activator Substances 0.000 description 4
- ILOJFJBXXANEQW-UHFFFAOYSA-N aminooxy(phenyl)borinic acid Chemical compound NOB(O)C1=CC=CC=C1 ILOJFJBXXANEQW-UHFFFAOYSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 230000009881 electrostatic interaction Effects 0.000 description 4
- -1 phenylboronic acid modified sodium alginate Chemical class 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 239000012670 alkaline solution Substances 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000002266 amputation Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- MDCWDBMBZLORER-UHFFFAOYSA-N triphenyl borate Chemical compound C=1C=CC=CC=1OB(OC=1C=CC=CC=1)OC1=CC=CC=C1 MDCWDBMBZLORER-UHFFFAOYSA-N 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0038—Gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0004—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0033—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0085—Porous materials, e.g. foams or sponges
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0024—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
- C08B37/0027—2-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
- C08B37/003—Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0084—Guluromannuronans, e.g. alginic acid, i.e. D-mannuronic acid and D-guluronic acid units linked with alternating alpha- and beta-1,4-glycosidic bonds; Derivatives thereof, e.g. alginates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
- C08H1/00—Macromolecular products derived from proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Materials Engineering (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
技术领域technical field
本发明涉及生物医用材料、组织工程和再生医学的技术领域,尤其是指一种用于糖尿病溃疡的负载生物活性玻璃的多功能创面修复敷料及其制备方法。The invention relates to the technical fields of biomedical materials, tissue engineering and regenerative medicine, in particular to a multifunctional wound repair dressing loaded with bioactive glass for diabetic ulcers and a preparation method thereof.
背景技术Background technique
糖尿病性溃疡是糖尿病最严重的并发症之一,伴有愈合延迟和过度炎症以及细胞外基质功能受损。糖尿病足溃疡已成为许多国家截肢的主要原因。影响糖尿病溃疡愈合主要原因是血管网损伤和细菌感染。血管网络的重建和细菌的消除对糖尿病溃疡的治疗至关重要。除了对患者进行血糖的控制,糖尿病溃疡的治疗常常借助一些功能材料来实现。然而目前临床上的大多数材料存在功能单一且生物活性低的缺点,无法有效地修复创面。Diabetic ulcers are one of the most serious complications of diabetes, with delayed healing and excessive inflammation and impaired extracellular matrix function. Diabetic foot ulcers have become the leading cause of amputations in many countries. The main factors affecting the healing of diabetic ulcers are vascular network damage and bacterial infection. Reconstruction of the vascular network and elimination of bacteria are crucial for the treatment of diabetic ulcers. In addition to controlling blood sugar in patients, the treatment of diabetic ulcers is often achieved with the help of some functional materials. However, most of the current clinical materials have the disadvantages of single function and low biological activity, and cannot effectively repair wounds.
水凝胶能够吸附组织渗出液,保持创面水分及时交换创面附近的气体(O2、CO2等),是创面修复的最佳材料。更重要的是,水凝胶的性能具有可设计性,能够根据临床实际需求设计出具有抗菌、自愈合、黏附等多功能水凝胶,以提高其实用性。同时水凝胶也是生物活性物质的优良载体。具有生物活性的敷料能够从内源性通道来加快创面修复。临床上常常使用生长因子来实现生物活性,然而由于其存在价格昂贵且半衰期短的缺点限制了应用。介孔生物活性玻璃(MBGs)是一种具有高比表面积、高生物活性和相容性的无机修复材料,能够促进血管的形成、细胞外基质(ECM)和胶原纤维的沉积加快创面愈合。因此,基于实用性的负载生物活性玻璃的多功能创面修复敷料为糖尿病溃疡的治疗提供一种可替代材料。Hydrogel can absorb tissue exudate, maintain wound moisture and exchange gas (O 2 , CO 2 , etc.) near the wound in time, and is the best material for wound repair. More importantly, the performance of hydrogels can be designed, and multifunctional hydrogels with antibacterial, self-healing, and adhesion properties can be designed according to actual clinical needs to improve their practicability. At the same time, hydrogel is also an excellent carrier for biologically active substances. Bioactive dressings can accelerate wound repair from endogenous channels. Growth factors are often used clinically to achieve biological activity, but their disadvantages of high price and short half-life limit their application. Mesoporous bioactive glasses (MBGs) are inorganic repair materials with high specific surface area, high bioactivity and compatibility, which can promote the formation of blood vessels, the deposition of extracellular matrix (ECM) and collagen fibers to accelerate wound healing. Therefore, the multifunctional wound repair dressing loaded with bioactive glass based on practicality provides an alternative material for the treatment of diabetic ulcers.
发明内容Contents of the invention
本发明的目的在于克服现有技术的缺点与不足,提出了一种用于糖尿病溃疡的负载生物活性玻璃的多功能创面修复敷料及其制备方法,该敷料通过苯硼酸酯和静电作用动态键制得,具有可注射性、自适应性、自愈合性、粘附性、抗菌性以及生物活性,能够很好地注射并粘附在创面处,具有良好的创面修复效果。The purpose of the present invention is to overcome the shortcomings and deficiencies of the prior art, and propose a multifunctional wound repair dressing for diabetic ulcers loaded with bioactive glass and a preparation method thereof. The preparation has injectability, self-adaptability, self-healing property, adhesiveness, antibacterial property and biological activity, can be well injected and adhered to the wound surface, and has good wound repair effect.
为实现上述目的,本发明所提供的技术方案为:负载生物活性玻璃的多功能创面修复敷料的制备方法,包括以下步骤:In order to achieve the above object, the technical solution provided by the present invention is: a method for preparing a multifunctional wound repair dressing loaded with bioactive glass, comprising the following steps:
1)使用十六烷基三甲基溴化铵(CTAB)和乙酸乙酯(EA)形成微乳体系,加入碱溶液腐蚀模板并作为体系催化剂,接着依次加入正硅酸四乙酯、磷酸三乙酯、四水合硝酸钙进行溶胶-凝胶反应制得介孔生物活性玻璃微球;1) Use cetyltrimethylammonium bromide (CTAB) and ethyl acetate (EA) to form a microemulsion system, add alkaline solution to corrode the template and act as a system catalyst, then add tetraethyl orthosilicate, triphosphate Mesoporous bioactive glass microspheres were prepared by sol-gel reaction of ethyl ester and calcium nitrate tetrahydrate;
将季铵盐改性聚合物材料溶解在PBS中,得到A溶液,将苯硼酸改性聚合物材料溶解在PBS中,得到B溶液;其中,季铵盐改性聚合物材料和苯硼酸改性聚合物材料是以不同的浓度溶解在PBS中;Dissolve the quaternary ammonium salt modified polymer material in PBS to obtain A solution, dissolve the phenylboronic acid modified polymer material in PBS to obtain B solution; wherein, the quaternary ammonium salt modified polymer material and phenylboronic acid modified Polymer materials are dissolved in PBS at different concentrations;
2)将制备的介孔生物活性玻璃微球以特定浓度加入到A溶液或者B溶液中并搅拌均匀,得到C溶液,然后再将没有加入介孔生物活性玻璃微球的A溶液或者B溶液与C溶液混合,即可快速制得具有自愈合性、抗菌性和生物活性的水凝胶作为创面修复敷料使用,最后,在室温下继续搅拌预设时间,以确保生成的水凝胶稳定。2) Add the prepared mesoporous bioactive glass microspheres to A solution or B solution at a specific concentration and stir evenly to obtain C solution, and then mix A solution or B solution without mesoporous bioactive glass microspheres with C solution is mixed, and a self-healing, antibacterial and bioactive hydrogel can be quickly prepared as a wound repair dressing. Finally, stirring is continued at room temperature for a preset time to ensure the stability of the generated hydrogel.
优选的,在步骤1)中,所述碱溶液为氨水溶液、氢氧化钠溶液或十二胺溶液;所述四水合硝酸钙的加入量为2-20g。Preferably, in step 1), the alkaline solution is ammonia solution, sodium hydroxide solution or dodecylamine solution; the added amount of calcium nitrate tetrahydrate is 2-20g.
优选的,在步骤1)中,所述季铵盐改性聚合物材料为明胶、壳聚糖、胶原、羧甲基壳聚糖中的一种或两种以上的组合。Preferably, in step 1), the quaternary ammonium salt-modified polymer material is one or a combination of two or more of gelatin, chitosan, collagen, and carboxymethyl chitosan.
优选的,在步骤1)中,所述苯硼酸改性聚合物材料为海藻酸钠、壳聚糖、明胶、葡聚糖、透明质酸中的一种或两种以上的组合。Preferably, in step 1), the phenylboronic acid-modified polymer material is one or a combination of two or more of sodium alginate, chitosan, gelatin, dextran, and hyaluronic acid.
优选的,在步骤1)中,所述季铵盐改性聚合物材料的浓度为1-5wt%,所述苯硼酸改性聚合物材料的浓度为1-5wt%。Preferably, in step 1), the concentration of the quaternary ammonium salt modified polymer material is 1-5 wt%, and the concentration of the phenylboronic acid modified polymer material is 1-5 wt%.
优选的,在步骤2)中,所述介孔生物活性玻璃微球的添加量为0.2-2wt%。Preferably, in step 2), the added amount of the mesoporous bioactive glass microspheres is 0.2-2wt%.
优选的,在步骤1)中,所述介孔生物活性玻璃微球的制备方法如下:将0.5-5mLCTAB溶解在去离子水中,待CTAB完全溶解后,加入5-50mL的EA形成微乳体系;待微乳体系稳定后,逐滴加入5-50mL的碱溶液;搅拌预设时间后,滴加5-20mL正硅酸乙酯(TEOS)继续搅拌预设时间;接着,每隔一段时间依次加入0.5-5mL磷酸三乙酯(TEP)、2-20g四水合硝酸钙(CN);然后在设定温度下再搅拌2-12h;静置陈化12-24h后,用无水乙醇和去离子水离心洗涤,得到粗产物;最后,将粗产物在500-800℃空气中烧结2-8h去除CTAB、EA、乙醇和反应单体,得到最终产品,即为介孔生物活性玻璃微球。Preferably, in step 1), the preparation method of the mesoporous bioactive glass microspheres is as follows: 0.5-5mL CTAB is dissolved in deionized water, and after CTAB is completely dissolved, 5-50mL of EA is added to form a microemulsion system; After the microemulsion system is stable, add 5-50mL of alkali solution dropwise; after stirring for the preset time, add 5-20mL tetraethyl orthosilicate (TEOS) dropwise and continue stirring for the preset time; then, add 0.5-5mL triethyl phosphate (TEP), 2-20g calcium nitrate tetrahydrate (CN); then stir at the set temperature for 2-12h; Centrifugal washing with water to obtain a crude product; finally, sintering the crude product in air at 500-800°C for 2-8 hours to remove CTAB, EA, ethanol and reaction monomers to obtain the final product, which is mesoporous bioactive glass microspheres.
优选的,在步骤1)中,所述季铵盐改性聚合物材料的制备方法如下:将聚合物材料2-10wt%的浓度溶于醋酸的水溶液中,在25-55℃下完全溶解,得到混合物;接着,将缩水甘油基三甲基氯化铵GTMAC加入上述混合物中,其中按照缩水甘油基三甲基氯化铵GTMAC与聚合物材料上的氨基1:1-5:1的比例加入,加入后在25-55℃下搅拌反应10-24h;然后将反应产物离心,去除未反应物质;最后,在去离子水透析后通过冷冻干燥得到季铵盐改性聚合物材料。Preferably, in step 1), the preparation method of the quaternary ammonium salt-modified polymer material is as follows: dissolve the polymer material in an aqueous solution of acetic acid at a concentration of 2-10 wt%, and dissolve it completely at 25-55°C, A mixture is obtained; then, glycidyl trimethyl ammonium chloride GTMAC is added to the above mixture, wherein it is added according to the ratio of glycidyl trimethyl ammonium chloride GTMAC to the amino group on the polymer material 1:1-5:1 , after the addition, stir and react at 25-55°C for 10-24h; then centrifuge the reaction product to remove unreacted substances; finally, obtain the quaternary ammonium salt modified polymer material by freeze-drying after deionized water dialysis.
优选的,在步骤1)中,所述苯硼酸改性聚合物材料的制备方法如下:将聚合物材料溶于2-(N-吗啉)乙磺酸(MES)溶液中得到浓度为0.5-2wt%的溶液,加入羧基活化剂活化20-60分钟,再加入氨基苯硼酸,在避光条件下连续搅拌12-48h,将反应液在去离子水中透析后冻干,得到苯硼酸改性聚合物材料。Preferably, in step 1), the preparation method of the phenylboronic acid modified polymer material is as follows: the polymer material is dissolved in 2-(N-morpholine) ethanesulfonic acid (MES) solution to obtain a concentration of 0.5- 2wt% solution, adding carboxyl activator to activate for 20-60 minutes, then adding aminophenylboronic acid, stirring continuously for 12-48h under dark conditions, dialyzing the reaction solution in deionized water and freeze-drying to obtain phenylboronic acid modified polymer material.
本发明也提供了一种由上述方法制备得到的负载生物活性玻璃的多功能创面修复敷料,用于糖尿病溃疡的创面愈合,该敷料具有自愈合性、抗菌性和生物活性,能够很好地注射并粘附在创面处,能够加速糖尿病创面的高质量愈合,具有良好的创面修复效果。The present invention also provides a multifunctional wound repairing dressing loaded with bioactive glass prepared by the above method, which is used for wound healing of diabetic ulcers. The dressing has self-healing, antibacterial and biological activities, and can well Injected and adhered to the wound, it can accelerate the high-quality healing of diabetic wounds and has a good wound repair effect.
本发明与现有技术相比,具有如下优点与有益效果:Compared with the prior art, the present invention has the following advantages and beneficial effects:
1、本发明将多功能水凝胶和生物活性玻璃结合,不仅为伤口愈合提供湿润的愈合环境,同时具备优异的抗菌、促成血管以及促愈合等功能,有效地解决了糖尿病溃疡病理环境复杂的问题,促进糖尿病创面的高质量愈合。1. The present invention combines multifunctional hydrogel with bioactive glass, which not only provides a moist healing environment for wound healing, but also has excellent antibacterial, blood vessel promoting and healing promoting functions, effectively solving the problem of complex pathological environment of diabetic ulcers. problem and promote high-quality healing of diabetic wounds.
2、本发明引入生物活性玻璃能够促进血管化相关因子的表达,有效解决了直接使用生长因子所带来的价格昂贵、利用度低等问题。2. The introduction of bioactive glass in the present invention can promote the expression of vascularization-related factors, effectively solving the problems of high price and low utilization caused by direct use of growth factors.
3、本发明对壳聚糖进行季铵盐修饰,不仅解决了壳聚糖水溶性差的问题,而且还提高了壳聚糖的抗菌性能。3. The present invention modifies chitosan with quaternary ammonium salt, which not only solves the problem of poor water solubility of chitosan, but also improves the antibacterial performance of chitosan.
4、本发明所制备水凝胶的原料均为天然高分子聚合物,不需要使用化学交联试剂,具有良好的生物相容性。4. The raw materials of the hydrogel prepared by the present invention are all natural high molecular polymers, without using chemical cross-linking reagents, and have good biocompatibility.
5、本发明所制备的水凝胶由静电作用和苯硼酸酯键制得,具有一定的力学强度,且具有优异的可注射,使其适用于各种不规则的伤口。同时良好的自愈合和黏附性能使其能够应用于关节处伤口,有效避免使用时因敷料脱落和断裂所导致的失效。5. The hydrogel prepared by the present invention is prepared by electrostatic interaction and phenylboronate bond, has certain mechanical strength, and has excellent injectability, making it suitable for various irregular wounds. At the same time, the good self-healing and adhesion properties enable it to be applied to joint wounds, effectively avoiding the failure caused by the dressing falling off and breaking during use.
附图说明Description of drawings
图1为实施例2本发明介孔生物活性玻璃的SEM图。Fig. 1 is a SEM image of the mesoporous bioactive glass of the present invention in Example 2.
图2为实施例2中所得到水凝胶的可注射性验证实物图。Fig. 2 is the physical picture of the injectability verification of the hydrogel obtained in Example 2.
图3为实施例2中所得到水凝胶的粘附性验证图。FIG. 3 is a verification diagram of the adhesion of the hydrogel obtained in Example 2. FIG.
图4为实施例2中所得到水凝胶的自愈合性验证图。FIG. 4 is a verification diagram of the self-healing property of the hydrogel obtained in Example 2.
具体实施方式Detailed ways
下面结合附图和实施例对本发明做进一步详细的描述,但本发明的实施方式不限于此。若未特别指明,实施例中所用的技术手段为本领域技术人员所熟知的常规手段。The present invention will be described in further detail below with reference to the accompanying drawings and examples, but the embodiments of the present invention are not limited thereto. Unless otherwise specified, the technical means used in the embodiments are conventional means well known to those skilled in the art.
以下所用季铵盐改性羧甲基壳聚糖的制备包括以下步骤:The preparation of quaternary ammonium salt modified carboxymethyl chitosan used below comprises the following steps:
将羧甲基壳聚糖以3wt%的浓度溶于醋酸的水溶液中,在40℃下完全溶解30min。接着按照缩水甘油基三甲基氯化铵(GTMAC)与羧甲基壳聚糖的氨基1:1加入GTMAC到上述混合物中,在55℃下搅拌反应10h。然后将反应产物以4500rpm的转速离心30min,去除未反应物质。将上清液倒入预冷的丙酮中,得到粗产物。将粗产物在去离子水中再溶解,然后在去离子水透析7d。最后通过冷冻干燥得到季铵盐改性羧甲基壳聚糖。Dissolve carboxymethyl chitosan in an aqueous solution of acetic acid at a concentration of 3 wt%, and dissolve completely at 40°C for 30 min. Then GTMAC was added to the above mixture according to the ratio of glycidyl trimethyl ammonium chloride (GTMAC) to the amino group of carboxymethyl chitosan at 1:1, and the reaction was stirred at 55° C. for 10 h. Then the reaction product was centrifuged at 4500 rpm for 30 min to remove unreacted substances. The supernatant was poured into pre-cooled acetone to obtain the crude product. The crude product was redissolved in deionized water and then dialyzed against deionized water for 7d. Finally, quaternary ammonium salt modified carboxymethyl chitosan was obtained by freeze-drying.
以下所用苯硼酸改性明胶的制备包括以下步骤:The preparation of phenylboronic acid modified gelatin used below comprises the following steps:
取5.33g 2-(N-吗啉)乙磺酸(MES)于500mL去离子水中,得到浓度为0.05mol/L的MES缓冲溶液;将5g明胶溶于500mL的MES缓冲溶液中得到浓度为1wt%的溶液,加入羧基活化剂活化30分钟,再加入适量的氨基苯硼酸,在避光条件下连续搅拌48h,将反应液在去离子水中透析3d后冻干,得到苯硼酸改性明胶。Get 5.33g 2-(N-morpholine) ethanesulfonic acid (MES) in 500mL deionized water, obtain the MES buffer solution that concentration is 0.05mol/L; Dissolve 5g gelatin in the MES buffer solution of 500mL and obtain concentration is 1wt % solution, adding a carboxyl activator to activate for 30 minutes, then adding an appropriate amount of aminophenylboronic acid, stirring continuously for 48 hours under dark conditions, dialyzing the reaction solution in deionized water for 3 days, and then freeze-drying to obtain phenylboronic acid-modified gelatin.
以下所用季铵盐改性胶原的制备包括以下步骤:The preparation of the quaternary ammonium salt modified collagen used below comprises the following steps:
将胶原以10wt%的浓度溶于醋酸的水溶液中,在25℃下完全溶解30min。接着按照缩水甘油基三甲基氯化铵(GTMAC)与胶原的氨基3:1加入GTMAC到上述混合物中,在55℃下搅拌反应24h。然后将反应产物以4500rpm的转速离心30min,去除未反应物质。然后在去离子水透析7d。最后通过冷冻干燥得到季铵盐改性胶原。The collagen was dissolved in an aqueous solution of acetic acid at a concentration of 10 wt%, and completely dissolved at 25° C. for 30 min. Then GTMAC was added to the above mixture according to the ratio of glycidyltrimethylammonium chloride (GTMAC) to the amino group of collagen at 3:1, and the mixture was stirred and reacted at 55° C. for 24 h. Then the reaction product was centrifuged at 4500 rpm for 30 min to remove unreacted substances. Then dialyzed in deionized water for 7 days. Finally, quaternary ammonium salt modified collagen was obtained by freeze-drying.
以下所用苯硼酸改性海藻酸钠的制备包括以下步骤:The preparation of phenylboronic acid modified sodium alginate used below comprises the following steps:
取5.33g 2-(N-吗啉)乙磺酸(MES)于500mL去离子水中,得到浓度为0.05mol/L的MES缓冲溶液。将4g海藻酸钠溶于200mL的MES缓冲溶液中得到浓度为2wt%的溶液,加入羧基活化剂活化60分钟,再加入适量的氨基苯硼酸,在避光条件下连续搅拌12h,将反应液在去离子水中透析3d后冻干,得到苯硼酸改性海藻酸钠。Take 5.33g of 2-(N-morpholine)ethanesulfonic acid (MES) in 500mL of deionized water to obtain a MES buffer solution with a concentration of 0.05mol/L. Dissolve 4g of sodium alginate in 200mL of MES buffer solution to obtain a solution with a concentration of 2wt%, add a carboxyl activator to activate it for 60 minutes, then add an appropriate amount of aminophenylboronic acid, and continue stirring for 12 hours under dark conditions. Dialyzed in deionized water for 3 days and then freeze-dried to obtain phenylboronic acid-modified sodium alginate.
以下所用季铵盐改性壳聚糖的制备包括以下步骤:The preparation of quaternary ammonium salt modified chitosan used below comprises the following steps:
将壳聚糖以2wt%的浓度溶于醋酸的水溶液中,在55℃下完全溶解30min。接着按照缩水甘油基三甲基氯化铵(GTMAC)与壳聚糖的氨基5:1加入GTMAC到上述混合物中,在55℃下搅拌反应15h。然后将反应产物以4500rpm的转速离心30min,去除未反应物质。将上清液倒入预冷的丙酮中,得到粗产物。将粗产物在去离子水中再溶解,然后在去离子水透析7d。最后通过冷冻干燥得到季铵盐改性壳聚糖。Dissolve chitosan in an aqueous solution of acetic acid at a concentration of 2 wt%, and dissolve completely at 55° C. for 30 min. Then add GTMAC to the above mixture according to glycidyl trimethylammonium chloride (GTMAC) and chitosan amino group 5:1, and stir and react at 55° C. for 15 h. Then the reaction product was centrifuged at 4500 rpm for 30 min to remove unreacted substances. The supernatant was poured into pre-cooled acetone to obtain the crude product. The crude product was redissolved in deionized water and then dialyzed against deionized water for 7d. Finally, quaternary ammonium salt modified chitosan was obtained by freeze-drying.
以下所用苯硼酸改性透明质酸的制备包括以下步骤:The preparation of phenylboronic acid modified hyaluronic acid used below comprises the following steps:
取5.33g 2-(N-吗啉)乙磺酸(MES)于500mL去离子水中,得到浓度为0.05mol/L的MES缓冲溶液。将1g透明质酸溶于200mL的MES缓冲溶液中得到浓度为0.5wt%的溶液,加入羧基活化剂活化20分钟,再加入适量的氨基苯硼酸,在避光条件下连续搅拌24h,将反应液在去离子水中透析3d后冻干,得到苯硼酸改性透明质酸。Take 5.33g of 2-(N-morpholine)ethanesulfonic acid (MES) in 500mL of deionized water to obtain a MES buffer solution with a concentration of 0.05mol/L. Dissolve 1 g of hyaluronic acid in 200 mL of MES buffer solution to obtain a solution with a concentration of 0.5 wt%, add a carboxyl activator to activate it for 20 minutes, then add an appropriate amount of aminophenylboronic acid, and continue stirring for 24 hours under light-shielding conditions. Dialyzed in deionized water for 3 days and then freeze-dried to obtain phenylboronic acid-modified hyaluronic acid.
实施例1Example 1
1、将2mL CTAB溶解在100mL去离子水中。待CTAB完全溶解后,加入30mL的EA形成微乳体系。待微乳体系稳定后,逐滴加入25mL十二胺溶液(2mol/L)。搅拌15min后,滴加10mL正硅酸乙酯(TEOS)继续搅拌30min。接着每隔30min依次加入1mL磷酸三乙酯(TEP)、8g四水合硝酸钙(CN)。然后在40℃下再搅拌4h。静置陈化12h后,用无水乙醇和去离子水离心洗涤三次,得到粗产物。最后将粗产物在500℃空气中烧结2h去除CTAB、EA、乙醇、反应单体等,得到介孔生物活性玻璃微球。1. Dissolve 2mL CTAB in 100mL deionized water. After CTAB was completely dissolved, 30mL of EA was added to form a microemulsion system. After the microemulsion system was stable, 25 mL of dodecylamine solution (2 mol/L) was added dropwise. After stirring for 15 min, 10 mL of tetraethyl orthosilicate (TEOS) was added dropwise and continued stirring for 30 min. Then, 1 mL of triethyl phosphate (TEP) and 8 g of calcium nitrate tetrahydrate (CN) were sequentially added every 30 min. It was then stirred at 40 °C for an additional 4 h. After standing and aging for 12 hours, it was centrifuged and washed three times with absolute ethanol and deionized water to obtain a crude product. Finally, the crude product was sintered in air at 500°C for 2 hours to remove CTAB, EA, ethanol, reactive monomers, etc., to obtain mesoporous bioactive glass microspheres.
2、将20mg季铵盐改性羧甲基壳聚糖和50mg苯硼酸改性明胶分别加入到1mLPBS中,然后在室温下搅拌24h,得到浓度为2wt%季铵盐改性羧甲基壳聚糖和5wt%苯硼酸改性明胶溶液。2. Add 20mg of quaternary ammonium salt-modified carboxymethyl chitosan and 50mg of phenylboronic acid-modified gelatin to 1mL PBS respectively, then stir at room temperature for 24h to obtain a concentration of 2wt% quaternary ammonium salt-modified carboxymethyl chitosan Sugar and 5 wt% phenylboronic acid modified gelatin solution.
3、将20mg介孔生物活性玻璃微球分散在1mL苯硼酸改性明胶溶液中,然后将季铵盐改性羧甲基壳聚糖快速加入上述体系,在室温下搅拌30min,即可得到稳定的水凝胶作为创面修复敷料使用,能够有效用于糖尿病溃疡的糖尿病创面的高质量愈合。3. Disperse 20 mg of mesoporous bioactive glass microspheres in 1 mL of phenylboronic acid-modified gelatin solution, then quickly add quaternary ammonium salt-modified carboxymethyl chitosan to the above system, and stir at room temperature for 30 minutes to obtain stable The hydrogel is used as a wound repair dressing, which can be effectively used for high-quality healing of diabetic wounds in diabetic ulcers.
实施例2Example 2
1、将0.5mL CTAB溶解在50mL去离子水中。待CTAB完全溶解后,加入5mL的EA形成微乳体系。待微乳体系稳定后,逐滴加入5mL的氨水溶液(2mol/L)。搅拌15min后,滴加5mL正硅酸乙酯(TEOS)继续搅拌30min。接着每隔30min依次加入0.5mL磷酸三乙酯(TEP)、2g四水合硝酸钙(CN)。然后在40℃下再搅拌12h。静置陈化24h后,用无水乙醇和去离子水离心洗涤三次,得到粗产物。最后将粗产物在800℃空气中烧结8h去除CTAB、EA、乙醇、反应单体等,得到介孔生物活性玻璃微球。1. Dissolve 0.5mL CTAB in 50mL deionized water. After CTAB was completely dissolved, 5 mL of EA was added to form a microemulsion system. After the microemulsion system was stable, 5 mL of ammonia solution (2 mol/L) was added dropwise. After stirring for 15 min, 5 mL of tetraethyl orthosilicate (TEOS) was added dropwise and continued stirring for 30 min. Then, 0.5 mL of triethyl phosphate (TEP) and 2 g of calcium nitrate tetrahydrate (CN) were sequentially added every 30 min. It was then stirred for another 12 h at 40 °C. After standing and aging for 24 hours, it was centrifuged and washed three times with absolute ethanol and deionized water to obtain a crude product. Finally, the crude product was sintered in air at 800°C for 8 hours to remove CTAB, EA, ethanol, and reactive monomers, etc., to obtain mesoporous bioactive glass microspheres.
2、将50mg季铵盐改性胶原和10mg苯硼酸改性透明质酸分别加入到1mLPBS中,然后在室温下搅拌24h,得到浓度为5wt%季铵盐改性胶原和1wt%苯硼酸改性透明质酸溶液。2. Add 50mg of quaternary ammonium salt-modified collagen and 10mg of phenylboronic acid-modified hyaluronic acid into 1mL PBS respectively, and then stir at room temperature for 24h to obtain a concentration of 5wt% quaternary ammonium salt-modified collagen and 1wt% phenylboronic acid-modified Hyaluronic acid solution.
3、将5mg介孔生物活性玻璃微球分散在1mL苯硼酸改性透明质酸溶液中,然后将季铵盐改性胶原快速加入上述体系,在室温下搅拌30min,即可得到稳定的水凝胶作为创面修复敷料使用,能够有效用于糖尿病溃疡的糖尿病创面的高质量愈合。3. Disperse 5 mg of mesoporous bioactive glass microspheres in 1 mL of phenylboronic acid-modified hyaluronic acid solution, then quickly add quaternary ammonium salt-modified collagen to the above system, and stir at room temperature for 30 minutes to obtain a stable hydrogel Glue is used as a wound repair dressing and can be effectively used for high-quality healing of diabetic ulcers in diabetic wounds.
本实施例的介孔生物活性玻璃微球的形貌如图1所示,介孔生物活性玻璃微球的制备首先由CTAB和EA形成微乳体系作为模板剂,接着加入碱溶液促进EA的水解,腐蚀微乳结构。TEOS和TEP加入后,随着碱溶液对模板剂的腐蚀,溶胶-凝胶反应由外向内逐步进行,进而得到具有介孔结构的生物活性玻璃微球。SEM显示生物活性玻璃微球具有规则的球形结构且表面存在有明显的孔结构,粒径均一,在300nm左右。The morphology of the mesoporous bioactive glass microspheres in this example is shown in Figure 1. The preparation of the mesoporous bioactive glass microspheres firstly forms a microemulsion system with CTAB and EA as a template, and then adds an alkali solution to promote the hydrolysis of EA. , corrode the microemulsion structure. After TEOS and TEP were added, the sol-gel reaction proceeded gradually from the outside to the inside as the alkali solution corroded the template, and then bioactive glass microspheres with mesoporous structure were obtained. SEM showed that the bioactive glass microspheres had a regular spherical structure and obvious pore structure on the surface, with a uniform particle size of about 300nm.
本实施例水凝胶的可注射性能展示如图2所示,水凝胶的网络结构由苯硼酸酯和静电作用构成,苯硼酸酯是一种可逆的动态化学键,静电作用是一种可逆的物理作用力,都具备快速的断裂和生成的能力。因此,水凝胶在受到强的剪切力作用时会发生断裂,剪切力撤去后能够快速地恢复其作用力。宏观上表现为水凝胶能够从16G针头中注射而出,且能够快速成型,说明了水凝胶具备良好的注射性。The injectable performance of the hydrogel in this example is shown in Figure 2. The network structure of the hydrogel is composed of phenyl borate and electrostatic interaction. Phenyl boron ester is a reversible dynamic chemical bond, and electrostatic interaction is a kind of Reversible physical forces have the ability to break and generate quickly. Therefore, the hydrogel will break when subjected to a strong shear force, and can quickly recover its force after the shear force is removed. Macroscopically, the hydrogel can be injected from a 16G needle and can be rapidly molded, indicating that the hydrogel has good injectability.
本实施例水凝胶的黏附性能如图3所示,苯硼酸的结构类似于多巴胺,可以与皮肤组织形成氢键等作用力,进而实现良好的黏附作用。从图3可知,水凝胶能够黏附在人类手指上,且随着手指的拉伸也不会出现脱落的现象,证实了水凝胶良好的组织黏附性。The adhesion performance of the hydrogel in this example is shown in Figure 3. The structure of phenylboronic acid is similar to that of dopamine, which can form hydrogen bonds and other forces with skin tissue, thereby achieving good adhesion. It can be seen from Figure 3 that the hydrogel can adhere to the human finger and will not fall off as the finger is stretched, which confirms the good tissue adhesion of the hydrogel.
本实施例的自愈合性能如图4所示,敷料在应用于关节处伤口时常常会因为运动导致敷料的断裂而失效,因而具备自愈合性能的水凝胶敷料是十分必要的。水凝胶由动态的苯硼酸酯和静电作用键形成,遭到外界作用破坏后,当再次接触时能够迅速结合,使得水凝胶愈合。宏观上表现为两个断裂的水凝胶在30s接触后,能够快速地愈合,形成整块凝胶。The self-healing performance of this embodiment is shown in Figure 4. When the dressing is applied to joint wounds, it often fails due to the breakage of the dressing due to movement. Therefore, a hydrogel dressing with self-healing performance is very necessary. The hydrogel is formed by dynamic phenylboronate and electrostatic interaction bonds. After being damaged by external effects, it can quickly combine when it is in contact again, so that the hydrogel can heal. Macroscopically, the two fractured hydrogels can quickly heal and form a whole gel after 30s of contact.
实施例3Example 3
1、将5mL CTAB溶解在一定量的去离子水中。待CTAB完全溶解后,加入50mL的EA形成微乳体系。待微乳体系稳定后,逐滴加入50mL的氢氧化钠溶液(2mol/L)。搅拌15min后,滴加20mL正硅酸乙酯(TEOS)继续搅拌30min。接着每隔30min依次加入5mL磷酸三乙酯(TEP)、20g四水合硝酸钙(CN)。然后在40℃下再搅拌2h。静置陈化16h后,用无水乙醇和去离子水离心洗涤三次,得到粗产物。最后将粗产物在650℃空气中烧结3h去除CTAB、EA、乙醇、反应单体等,得到介孔生物活性玻璃微球。1. Dissolve 5mL CTAB in a certain amount of deionized water. After CTAB was completely dissolved, 50mL of EA was added to form a microemulsion system. After the microemulsion system was stable, 50 mL of sodium hydroxide solution (2 mol/L) was added dropwise. After stirring for 15 min, 20 mL of tetraethyl orthosilicate (TEOS) was added dropwise and continued stirring for 30 min. Then, 5 mL of triethyl phosphate (TEP) and 20 g of calcium nitrate tetrahydrate (CN) were sequentially added every 30 min. It was then stirred for another 2 h at 40 °C. After standing and aging for 16 hours, it was centrifuged and washed three times with absolute ethanol and deionized water to obtain a crude product. Finally, the crude product was sintered in air at 650° C. for 3 h to remove CTAB, EA, ethanol, reactive monomers, etc., to obtain mesoporous bioactive glass microspheres.
2、将10mg季铵盐改性壳聚糖和50mg苯硼酸改性海藻酸钠分别加入到1mLPBS中,然后在室温下搅拌24h,得到浓度为1wt%季铵盐改性壳聚糖和5wt%苯硼酸改性海藻酸钠溶液。2. Add 10mg of quaternary ammonium salt-modified chitosan and 50mg of phenylboronic acid-modified sodium alginate to 1mL PBS respectively, then stir at room temperature for 24h to obtain a concentration of 1wt% quaternary ammonium salt-modified chitosan and 5wt% Phenylboronic acid modified sodium alginate solution.
3、将2mg介孔生物活性玻璃微球分散在1mL苯硼酸改性海藻酸钠溶液中,然后将季铵盐改性壳聚糖快速加入上述体系,在室温下搅拌30min,即可得到稳定的水凝胶作为创面修复敷料使用,能够有效用于糖尿病溃疡的糖尿病创面的高质量愈合。3. Disperse 2 mg of mesoporous bioactive glass microspheres in 1 mL of phenylboronic acid-modified sodium alginate solution, then quickly add quaternary ammonium salt-modified chitosan to the above system, and stir at room temperature for 30 minutes to obtain a stable The hydrogel is used as a wound repair dressing, which can be effectively used for high-quality healing of diabetic wounds in diabetic ulcers.
本发明的实施例仅仅是为清楚地说明本发明所举的例子,而并非是对本发明的实施方式的限定。对于所属领域的专业人员而言,在上述实施例的基础上还可以做出其他不同形式的变化或变动,这里无需也无法对所有的实施方式予以穷举。凡在本发明的精神和原则之内所做的任何修改,等同替换和改进等,均应包含在本发明权利要求的保护范围之内。The embodiments of the present invention are merely examples for clearly illustrating the present invention, rather than limiting the implementation of the present invention. For those skilled in the art, other changes or changes in different forms can be made on the basis of the above-mentioned embodiments, and it is not necessary and impossible to exhaustively enumerate all the implementation manners here. Any modification, equivalent replacement and improvement made within the spirit and principle of the present invention shall be included in the protection scope of the claims of the present invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310031729.4A CN116139331A (en) | 2023-01-10 | 2023-01-10 | Multifunctional wound repair dressing loaded with bioactive glass and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310031729.4A CN116139331A (en) | 2023-01-10 | 2023-01-10 | Multifunctional wound repair dressing loaded with bioactive glass and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116139331A true CN116139331A (en) | 2023-05-23 |
Family
ID=86374076
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310031729.4A Pending CN116139331A (en) | 2023-01-10 | 2023-01-10 | Multifunctional wound repair dressing loaded with bioactive glass and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116139331A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116688222A (en) * | 2023-06-27 | 2023-09-05 | 暨南大学附属第一医院(广州华侨医院) | A smart responsive hydrogel dressing based on hypoxic exosomes and its preparation method and application |
CN117142767A (en) * | 2023-07-04 | 2023-12-01 | 景德镇陶瓷大学 | A method for preparing zinc-doped radial mesoporous bioactive glass microspheres with immune regulation function and products prepared therefrom |
CN118121774A (en) * | 2024-05-08 | 2024-06-04 | 四川大学 | Strontium-doped bioactive glass/gelatin nanofiber microsphere as well as preparation method and application thereof |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104386699A (en) * | 2014-11-05 | 2015-03-04 | 上海大学 | Method for preparing multi-shell mesoporous silicon oxide nanomaterial by dual-template method |
CN105169487A (en) * | 2015-10-27 | 2015-12-23 | 上海交通大学 | Wound healing cell sheet with biological activity, preparing method and application |
CN106606805A (en) * | 2015-10-22 | 2017-05-03 | 中国科学院上海硅酸盐研究所 | Novel nanometer bioglass-coated patterned electrospun fiber membrane and its preparation method and use |
CN108083618A (en) * | 2017-12-15 | 2018-05-29 | 华南理工大学 | A kind of micro-nano bioactivity glass microballoon prepared using microemulsion technology and preparation method thereof |
CN111905151A (en) * | 2020-04-30 | 2020-11-10 | 华南理工大学 | Mesoporous bioactive glass/polylactic acid-glycolic acid copolymer composite microsphere and preparation method and application thereof |
CN112618781A (en) * | 2020-11-30 | 2021-04-09 | 华南理工大学 | Mesoporous bioactive glass/chitosan composite hemostatic sponge and preparation method thereof |
WO2021223756A1 (en) * | 2020-05-08 | 2021-11-11 | 四川大学 | Injectable hydrogel having anti-inflammatory and repair-promoting function, preparation method therefor and application thereof in heart repair |
CN113941026A (en) * | 2021-10-25 | 2022-01-18 | 浙江中医药大学 | Bioactive glass-coated chitosan cellulose derivative-based injectable hydrogel dressing and preparation method thereof |
CN114288465A (en) * | 2021-12-20 | 2022-04-08 | 华南理工大学 | Bioactive nano composite hydrogel dressing and preparation method thereof |
CN115068684A (en) * | 2022-06-30 | 2022-09-20 | 华南理工大学 | Curcumin-loaded hydrogel for chronic diabetic wound repair and preparation method thereof |
-
2023
- 2023-01-10 CN CN202310031729.4A patent/CN116139331A/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104386699A (en) * | 2014-11-05 | 2015-03-04 | 上海大学 | Method for preparing multi-shell mesoporous silicon oxide nanomaterial by dual-template method |
CN106606805A (en) * | 2015-10-22 | 2017-05-03 | 中国科学院上海硅酸盐研究所 | Novel nanometer bioglass-coated patterned electrospun fiber membrane and its preparation method and use |
CN105169487A (en) * | 2015-10-27 | 2015-12-23 | 上海交通大学 | Wound healing cell sheet with biological activity, preparing method and application |
CN108083618A (en) * | 2017-12-15 | 2018-05-29 | 华南理工大学 | A kind of micro-nano bioactivity glass microballoon prepared using microemulsion technology and preparation method thereof |
CN111905151A (en) * | 2020-04-30 | 2020-11-10 | 华南理工大学 | Mesoporous bioactive glass/polylactic acid-glycolic acid copolymer composite microsphere and preparation method and application thereof |
WO2021223756A1 (en) * | 2020-05-08 | 2021-11-11 | 四川大学 | Injectable hydrogel having anti-inflammatory and repair-promoting function, preparation method therefor and application thereof in heart repair |
CN112618781A (en) * | 2020-11-30 | 2021-04-09 | 华南理工大学 | Mesoporous bioactive glass/chitosan composite hemostatic sponge and preparation method thereof |
CN113941026A (en) * | 2021-10-25 | 2022-01-18 | 浙江中医药大学 | Bioactive glass-coated chitosan cellulose derivative-based injectable hydrogel dressing and preparation method thereof |
CN114288465A (en) * | 2021-12-20 | 2022-04-08 | 华南理工大学 | Bioactive nano composite hydrogel dressing and preparation method thereof |
CN115068684A (en) * | 2022-06-30 | 2022-09-20 | 华南理工大学 | Curcumin-loaded hydrogel for chronic diabetic wound repair and preparation method thereof |
Non-Patent Citations (2)
Title |
---|
林才等: "溶胶-凝胶生物活性玻璃的结构特征及其对糖尿病创面修复作用的研究", 《第八届全国创伤修复(愈合)与组织再生学术交流会论文集》, 29 October 2013 (2013-10-29), pages 329 - 335 * |
陈星陶等: "介孔生物玻璃微球/羧甲基纤维素复合可吸收止血材料", 《高分子材料科学与工程》, vol. 36, no. 6, 30 June 2020 (2020-06-30), pages 118 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116688222A (en) * | 2023-06-27 | 2023-09-05 | 暨南大学附属第一医院(广州华侨医院) | A smart responsive hydrogel dressing based on hypoxic exosomes and its preparation method and application |
CN116688222B (en) * | 2023-06-27 | 2024-05-07 | 暨南大学附属第一医院(广州华侨医院) | A smart responsive hydrogel dressing based on hypoxic exosomes and its preparation method and application |
CN117142767A (en) * | 2023-07-04 | 2023-12-01 | 景德镇陶瓷大学 | A method for preparing zinc-doped radial mesoporous bioactive glass microspheres with immune regulation function and products prepared therefrom |
CN118121774A (en) * | 2024-05-08 | 2024-06-04 | 四川大学 | Strontium-doped bioactive glass/gelatin nanofiber microsphere as well as preparation method and application thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN116139331A (en) | Multifunctional wound repair dressing loaded with bioactive glass and preparation method thereof | |
CN103446621B (en) | Preparation method of nano-silver-containing sodium alginate based antibacterial medical dressing | |
CN108467498B (en) | A kind of supramolecular hydrogel of chitosan and gelatin and its preparation method and application | |
CN114668897B (en) | Antibacterial, adhesive and self-healing hydrogel and preparation method and application thereof | |
CN109796606B (en) | Self-healing hydrogel based on multiple dynamic chemical bonds and preparation method thereof | |
CN114288465A (en) | Bioactive nano composite hydrogel dressing and preparation method thereof | |
CN112546288A (en) | Hydrogel dressing capable of dissolving according to needs and preparation method thereof | |
CN113372585A (en) | Preparation method and application of hydrogel with high-adhesion composite function | |
CN107915848A (en) | A kind of preparation method of chitin whisker/hydroxyl butyl chitosan temperature-sensitive hydrogel | |
CN106496608B (en) | Collagen-based compounds the preparation method of non-ionic polysaccharide building composite hydrogel | |
CN104958251A (en) | Preparation method of hyaluronic acid nanogel | |
WO2023169074A1 (en) | Bone adhesive, preparation method therefor and application thereof | |
CN112089886A (en) | A kind of hydrogel and preparation method thereof | |
CN112807483B (en) | Anti-inflammatory, antibacterial and hemostatic double-network hydrogel and preparation method and application thereof | |
CN115554462A (en) | Anti-swelling injectable hydrogel adhesive and preparation method thereof | |
CN115382008B (en) | Preparation method of injectable hydrogel suitable for diabetic wound repair | |
CN115536919B (en) | A modified chitosan adhesive hydrogel and its preparation method and application | |
CN114588309B (en) | Preparation method of double-crosslinked multi-micropore hemostatic sponge | |
CN115317661A (en) | Natural polymer composite hydrogel dressing | |
CN102432895B (en) | Preparation method of temperature-sensitive cellulose quaternary ammonium salt/beta-sodium glycerophosphate hydrogel | |
CN108478852A (en) | A kind of pharmaceutical products, the carrier for loading pharmaceutical products, hydrogel and its method | |
CN108939132A (en) | A kind of high bioactivity hyaluronic acid medical film and preparation method thereof based on the modification of low immunogenicity collagen | |
CN106540315B (en) | Preparation method of spray-type chitosan aqueous wound dressing | |
CN117122729A (en) | Preparation method and application of tissue-adhesive hydrogel | |
CN114230820B (en) | Double-network self-healing hydrogel encapsulating bioglass and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |